LXRX earnings analysis
What we found in LXRX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Lexicon Pharmaceuticals reported disappointing Q1 2026 results with revenues of only $1.09 million, missing estimates of $9.57 million by a significant margin. EPS was flat at $0.00, slightly exceeding expectations of -$0.04. The company noted challenges in maintaining its financial position and addressing a high cash burn rate.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Falls Short of Expectations
- Actual revenue of $1.09M significantly missed the estimated $9.57M by 88.6%.
- EPS Matches Expectations
- Reported EPS was $0.00, slightly better than the expected -$0.04.
- Cash Burn Rate Remains High
- Continues to experience negatives with high cash burn, affecting liquidity.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Cash Burn Rate
- Company reported ongoing high cash burn, affecting liquidity and future operations.
- Dependence on Drug Development Success
- Risk of failure in R&D could adversely affect future revenue and stock price.
- Regulatory Approval Uncertainties
- Lengthy regulatory processes may lead to delays in product commercialization.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.0
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads worse than the one before it.
What came before.
- 10-K · March 5, 2026
- Lexicon’s 2025 results show a sharp rebound in reported revenue driven by collaboration/licensing proceeds (Novo Nordisk $45.0M upfront) and a materially narrower net loss (‑$50.3M vs ‑$200.4M in 2024) after large…
- 10-Q · May 14, 2025
- Lexicon reported Q1 2025 revenue of $1,262,000 (net product revenue) and a net loss of $25,295,000 (EPS $(0.07)), an improvement versus Q1 2024 net loss of $48,397,000 (EPS $(0.20)). The quarter reflects a one-time…
- 10-K · March 7, 2025
- Lexicon pivoted in 2024 toward commercialization and licensing while continuing R&D on pilavapadin (LX9211), LX9851 and sotagliflozin. Revenue rose to approximately $31.1 million in 2024 driven by a $25.0 million…
- 10-Q · November 13, 2024
- Lexicon reported Q3 net revenue of $1,750,000 and maintained a high gross margin (~95.9%), but posted a large operating loss of $63,693,000 and a net loss of $64,811,000 (EPS -$0.18). Liquidity was materially…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing LXRX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever